2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
2seventy bio (TSVT) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, with a conference call and webcast at 8:00 a.m. ET. The company's management will also present at Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 13, 2024, at 10:00 a.m. ET. Both events will be accessible through the company's investor relations website, with conference replays available for 30 days following the events.
2seventy bio (TSVT) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024, con una teleconferenza e webcast alle 8:00 a.m. ET. La direzione dell'azienda parteciperà anche alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim a Boston il 13 novembre 2024, alle 10:00 a.m. ET. Entrambi gli eventi saranno accessibili tramite il sito web delle relazioni con gli investitori dell'azienda, con le registrazioni delle conferenze disponibili per 30 giorni dopo gli eventi.
2seventy bio (TSVT) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024, con una conferencia telefónica y webcast a las 8:00 a.m. ET. La dirección de la empresa también presentará en la Conferencia Inaugural de Innovación en Salud de Guggenheim en Boston el 13 de noviembre de 2024, a las 10:00 a.m. ET. Ambos eventos serán accesibles a través del sitio web de relaciones con inversores de la empresa, con repeticiones de la conferencia disponibles durante 30 días después de los eventos.
2seventy bio (TSVT)는 2024년 3분기 재무 결과 발표를 2024년 11월 12일 화요일 오전 8시(ET)에 진행할 예정입니다. 회사 경영진은 또한 2024년 11월 13일 오전 10시(ET)에 보스턴에서 열리는 구겐하임의 첫 번째 헬스케어 혁신 컨퍼런스에 참석할 예정입니다. 두 행사 모두 회사의 투자자 관계 웹사이트를 통해 접근 가능하며, 행사 후 30일 동안 컨퍼런스 재생이 제공됩니다.
2seventy bio (TSVT) a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 pour le mardi 12 novembre 2024, avec une conférence téléphonique et un webcast à 8h00 HAE. La direction de l'entreprise présentera également lors de la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim à Boston le 13 novembre 2024 à 10h00 HAE. Les deux événements seront accessibles via le site Web des relations avec les investisseurs de l'entreprise, avec des rediffusions de la conférence disponibles pendant 30 jours après les événements.
2seventy bio (TSVT) hat die Bekanntgabe der finanziellen Ergebnisse für das dritte Quartal 2024 auf Dienstag, den 12. November 2024, um 8:00 Uhr ET, angesetzt, mit einer Telefonkonferenz und einem Webcast. Das Management des Unternehmens wird auch am Ersten Gesundheitsinnovationskonferenz von Guggenheim in Boston am 13. November 2024 um 10:00 Uhr ET teilnehmen. Beide Veranstaltungen sind über die Website für Investorenbeziehungen des Unternehmens zugänglich, und es werden Aufzeichnungen der Konferenz für 30 Tage nach den Veranstaltungen verfügbar sein.
- None.
- None.
Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It’s recommended that participants join 10 minutes prior to the event’s start.
Members of the management team will also be presenting at the following upcoming investor conference:
-
Guggenheim’s Inaugural Healthcare Innovation Conference in
Boston, MA on Wednesday, November 13, 2024 at 10:00 a.m. ET
A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. Replays will be archived on 2seventy bio’s site for 30 days following the event.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104367323/en/
Investors and Media:
Vicki Eatwell, CFO
vicki.eatwell@2seventybio.com
Morgan (
Morgan.adams@2seventybio.com
Source: 2seventy bio, Inc.
FAQ
When will 2seventy bio (TSVT) report Q3 2024 earnings?
Where can I access TSVT's Q3 2024 earnings call?
Which investor conference will TSVT attend in November 2024?
